Business
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering
About this update from Alector, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 Presentations TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95594)Presenting Author: Arthur J. Mayorga, Ph.D., Vice President, Clinical Development Neurology, Alector Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET Poster Title: Use of a blood-based amyloid test for screening in INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer’s disease (#95646)Presenting Author: Brady Burgess, Ph.D., Staff Scientist, Alector Session Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET Progranulin PresentationsProgranulin Programs (latozinemab (AL001) and AL101/GSK4527226) are Being Developed in Collaboration with GSK Poster Title: Using plasma biomarkers to distinguish TDP43 associated pathologies (#89291)Presenting Author: Gopi Ganji, Ph.D., Scientific Leader, GSKSession Date and Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m. ET Poster Title: PROGRESS-AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti-sortilin monoclonal antibody, in patients with early Alzheimer's disease (#90247)Presenting Author: Christine Bailey, Ph.D., Clinical Development Director, GSK Session Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET Poster Topic: Genetics, progranulin, and Alzheimer’s disease (#89497)Presenting Author: Chun-Fand Xu, Ph.D., Senior Director, Human Genetics Senior Director, GSKSession Date and Time: Sunday, July 28, 2024 from 8:00 a.m. – 4:15 p.m. ET About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative ...